Cara Therapeutics (NASDAQ:CARA) Now Covered by StockNews.com

Equities research analysts at StockNews.com began coverage on shares of Cara Therapeutics (NASDAQ:CARA) in a report released on Monday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Cara Therapeutics Stock Performance

Shares of CARA stock opened at $5.32 on Monday. The firm has a market cap of $24.33 million, a price-to-earnings ratio of -0.25 and a beta of 0.41. Cara Therapeutics has a 52 week low of $8.13 and a 52 week high of $31.32. The firm’s 50-day simple moving average is $5.06 and its two-hundred day simple moving average is $4.39.

Hedge Funds Weigh In On Cara Therapeutics

Several institutional investors have recently bought and sold shares of CARA. FMR LLC raised its stake in shares of Cara Therapeutics by 18.5% in the third quarter. FMR LLC now owns 210,312 shares of the biopharmaceutical company’s stock valued at $65,000 after buying an additional 32,789 shares during the period. XTX Topco Ltd purchased a new stake in shares of Cara Therapeutics during the 3rd quarter valued at approximately $29,000. Shay Capital LLC bought a new position in Cara Therapeutics in the 4th quarter worth approximately $524,000. Rockefeller Capital Management L.P. purchased a new position in Cara Therapeutics in the 4th quarter valued at approximately $953,000. Finally, Curi RMB Capital LLC bought a new stake in Cara Therapeutics during the 4th quarter valued at $277,000. Hedge funds and other institutional investors own 44.66% of the company’s stock.

About Cara Therapeutics

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.